Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.23. The company had revenue of $36.02 million for the quarter, compared to analysts’ expectations of $36.03 million. The business’s quarterly revenue was up 30.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.13) EPS.
Vanda Pharmaceuticals (NASDAQ:VNDA) traded up 0.80% during trading on Wednesday, hitting $11.29. 519,672 shares of the stock traded hands. The firm has a 50-day moving average price of $11.17 and a 200 day moving average price of $9.27. Vanda Pharmaceuticals has a 52-week low of $6.91 and a 52-week high of $14.50. The company’s market cap is $487.20 million.
A number of analysts recently issued reports on the stock. Brean Capital restated a “buy” rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a report on Wednesday, April 27th. Jefferies Group restated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Sunday, May 29th. Finally, Zacks Investment Research downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 6th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $15.92.
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.
